Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Arcutis Biotherapeutics shares are trading higher after Cantor Fitzgerald initiated its coverage on the stock with an Overweight rating and announced a price target of $48.

Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.

Truist Securities Maintains Hold on Incyte, Raises Price Target to $115

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.